FILING ANALYSIS · TUESDAY, NOVEMBER 17
Nuo Therapeutics, Inc. AURX — 8-K: Results of Operations and Financial Condition
positive
Nuo Therapeutics reported an 80% increase in total revenues for the third quarter 2026 and a 123% increase for the first nine months of 2026, with Aurix wound care revenues growing 17% sequentially, and received final funding of $325,000 under a loan agreement, but also incurred higher stock-based compensation and regulatory costs, and is prioritizing reaching operational breakeven and assessing o
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →